Literature DB >> 30023286

Phenotypic variability of MTO1-deficiency.

Josef Finsterer1, Sinda Zarrouk-Mahjoub2.   

Abstract

Entities:  

Keywords:  Cardiac involvement; Epilepsy; Genotype; Mitochondrial; Multisystem disease; Phenotype

Year:  2018        PMID: 30023286      PMCID: PMC6047458          DOI: 10.1016/j.ymgmr.2018.01.003

Source DB:  PubMed          Journal:  Mol Genet Metab Rep        ISSN: 2214-4269


× No keyword cloud information.
We read with interest the article by O'Byrne et al. about the presentation of 2 and review of 35 patients with MTO1-deficiency [1]. We have the following comments and concerns. Patient-1 had febrile seizures since age 2.5y and absence seizures since age 3.5y [1]. Which antiepileptic drugs (AEDs) were administered during the course? This issue is crucial since some AEDs, such as valproic acid, carbamazepine, phenytoin, or phenobarbital may exhibit mitochondrion-toxic effects, and may worsen the phenotype [2]. Particularly valproic acid may exhibit severe side effects in patients with a mitochondrial disorder (MID) and may even cause death, particularly in patients carrying POLG1 mutations [3]. Seizures were refractory to treatment at age 11y [1]. Was refractoriness attributable to the mitochondrion-toxic effect of the applied AEDs? At age 11y patient-1 developed multiple, transient T2-hyperintensities within the peduncles, basal ganglia, and the cortex [1]. Were these imaging abnormalities stroke-like lesions, the morphological equivalent of stroke-like episodes (SLEs)? Did the phenotype deteriorate during this episode? Were these lesions hyperintense on DWI and ADC, thus indicative of a vasogenic edema, typical for a stroke-like lesion? Did the patient receive L-arginine during this episode, which is frequently recommended as acute treatment of SLEs [4]. Were other causes of the transient T2-hyperintensities, such as ADEM or an epiphenomenon of the seizure activity, considered? One of the dominant phenotypic features seems to be hypertrophic cardiomyopathy and arrhythmias (Table 1) [1]. How many of the analysed patients developed heart failure or systolic dysfunction and required cardiac therapy? Was non-compaction, frequently associated with MIDs [5], detected in any patient?
Table 1

Phenotypic features in 35 patients carrying MTO1 mutations.

FeatureNumber of patients
Brain
 Intellectual disability26
 Muscle hypotonia22
 Failure to thrive15
 Abnormal cerebral imaging15
 Seizures12
 Optic atrophy9
 Ataxia7
 Developmental delay6
 Dystonia1
Eyes
 Cataract1
 Pigmentary retinopathy1
Heart
 Hypertrophic cardiomyopathy27
 Cardiac arrhythmias8
 Dilated cardiomyopathy1
Muscle
 Lactic acidosis20
 Myopathy7
 Respiratory insufficiency5
Endocrine abnormalities
 Hypoglycemia2
 Short stature1
Gastrointestinal
 Feeding difficulties15
 Hepatopathy3
Renal
 Hypocalcemia1
 Tubulopathy1
Others
 Dysmorphism1
 Microcephaly1
 Hyper-ammonemia1
Phenotypic features in 35 patients carrying MTO1 mutations. Overall, this interesting study could be more meaningful by providing more details about the AED treatment and its influence on the phenotype, about the cerebral imaging findings, about the cardiac involvement in the disease, and about the family history.

Conflicts of interest

There are no conflicts of interest.

Funding

No funding was received.

Author contribution

JF: design, literature search, discussion, first draft, SZ-M: literature search, discussion, critical comments
  5 in total

Review 1.  Mitochondrial toxicity of antiepileptic drugs and their tolerability in mitochondrial disorders.

Authors:  Josef Finsterer; Sinda Zarrouk Mahjoub
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-12-07       Impact factor: 4.481

2.  Clinical and radiologic reversal of stroke-like episodes in MELAS with high-dose L-arginine.

Authors:  Ishita Siddiq; Elysa Widjaja; Ingrid Tein
Journal:  Neurology       Date:  2015-06-12       Impact factor: 9.910

3.  Acute liver failure after valproate exposure in patients with POLG1 mutations and the prognosis after liver transplantation.

Authors:  Johanna Hynynen; Tuomas Komulainen; Eija Tukiainen; Arno Nordin; Johanna Arola; Reetta Kälviäinen; Leena Jutila; Matias Röyttä; Reetta Hinttala; Kari Majamaa; Heikki Mäkisalo; Johanna Uusimaa
Journal:  Liver Transpl       Date:  2014-10-03       Impact factor: 5.799

Review 4.  Cardiogenetics, neurogenetics, and pathogenetics of left ventricular hypertrabeculation/noncompaction.

Authors:  Josef Finsterer
Journal:  Pediatr Cardiol       Date:  2009-01-29       Impact factor: 1.655

5.  The genotypic and phenotypic spectrum of MTO1 deficiency.

Authors:  James J O'Byrne; Maja Tarailo-Graovac; Aisha Ghani; Michael Champion; Charu Deshpande; Ali Dursun; Riza K Ozgul; Peter Freisinger; Ian Garber; Tobias B Haack; Rita Horvath; Ivo Barić; Ralf A Husain; Leo A J Kluijtmans; Urania Kotzaeridou; Andrew A Morris; Colin J Ross; Saikat Santra; Jan Smeitink; Mark Tarnopolsky; Saskia B Wortmann; Johannes A Mayr; Michaela Brunner-Krainz; Holger Prokisch; Wyeth W Wasserman; Ron A Wevers; Udo F Engelke; Richard J Rodenburg; Teck Wah Ting; Robert McFarland; Robert W Taylor; Ramona Salvarinova; Clara D M van Karnebeek
Journal:  Mol Genet Metab       Date:  2017-11-15       Impact factor: 4.797

  5 in total
  1 in total

1.  Proteomic and Metabolomic Analyses Provide Insights into the Mechanism on Arginine Metabolism Regulated by tRNA Modification Enzymes GidA and MnmE of Streptococcus suis.

Authors:  Ting Gao; Fangyan Yuan; Zewen Liu; Wei Liu; Danna Zhou; Keli Yang; Rui Guo; Wan Liang; Geng Zou; Rui Zhou; Yongxiang Tian
Journal:  Front Cell Infect Microbiol       Date:  2020-12-11       Impact factor: 5.293

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.